394 related articles for article (PubMed ID: 33922072)
1. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
[TBL] [Abstract][Full Text] [Related]
2. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Menzies-Gow A; Wechsler ME; Brightling CE
Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
[TBL] [Abstract][Full Text] [Related]
3. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.
Marone G; Spadaro G; Braile M; Poto R; Criscuolo G; Pahima H; Loffredo S; Levi-Schaffer F; Varricchi G
Expert Opin Investig Drugs; 2019 Nov; 28(11):931-940. PubMed ID: 31549891
[No Abstract] [Full Text] [Related]
4. Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma.
Pelaia C; Pelaia G; Longhini F; Crimi C; Calabrese C; Gallelli L; Sciacqua A; Vatrella A
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572294
[TBL] [Abstract][Full Text] [Related]
5. Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.
Bagnasco D; De Ferrari L; Bondi B; Candeliere MG; Mincarini M; Riccio AM; Braido F
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892164
[TBL] [Abstract][Full Text] [Related]
6. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
[TBL] [Abstract][Full Text] [Related]
7. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
Shinkai M; Yabuta T
Immunotherapy; 2023 Dec; 15(17):1435-1447. PubMed ID: 37724378
[TBL] [Abstract][Full Text] [Related]
8. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.
Kurihara M; Kabata H; Irie M; Fukunaga K
Allergol Int; 2023 Jan; 72(1):24-30. PubMed ID: 36470789
[TBL] [Abstract][Full Text] [Related]
9. Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses.
Nakajima S; Kabata H; Kabashima K; Asano K
Allergol Int; 2020 Apr; 69(2):197-203. PubMed ID: 31974038
[TBL] [Abstract][Full Text] [Related]
10. Tezepelumab for asthma.
Nolasco S; Pelaia C; Scioscia G; Campisi R; Crimi C
Drugs Today (Barc); 2022 Dec; 58(12):591-603. PubMed ID: 36651067
[TBL] [Abstract][Full Text] [Related]
11. Positioning of Tezepelumab in Severe Asthma.
Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
[TBL] [Abstract][Full Text] [Related]
12. Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma.
Salvati L; Maggi L; Annunziato F; Cosmi L
Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):590-596. PubMed ID: 34608100
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.
Roy P; Rafa ZI; Haque SN; Tasha T; Arko SB; Agrawal H; Razu MI; Parisapogu A; Maisha S; Siddique MA; Abbasi FK; Shama N; Dev Nath S; Ghosh AS; Quader F
Cureus; 2022 Dec; 14(12):e32156. PubMed ID: 36601189
[TBL] [Abstract][Full Text] [Related]
14. Development of an inhaled anti-TSLP therapy for asthma.
O'Byrne PM; Panettieri RA; Taube C; Brindicci C; Fleming M; Altman P
Pulm Pharmacol Ther; 2023 Feb; 78():102184. PubMed ID: 36535465
[TBL] [Abstract][Full Text] [Related]
15. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma.
Matera MG; Ora J; Rogliani P; Cazzola M
Expert Opin Drug Discov; 2023; 18(9):951-963. PubMed ID: 37387523
[TBL] [Abstract][Full Text] [Related]
16. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma.
Gauvreau GM; Sehmi R; Ambrose CS; Griffiths JM
Expert Opin Ther Targets; 2020 Aug; 24(8):777-792. PubMed ID: 32567399
[TBL] [Abstract][Full Text] [Related]
17. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A; Colice G; Griffiths JM; Almqvist G; Ponnarambil S; Kaur P; Ruberto G; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
Respir Res; 2020 Oct; 21(1):266. PubMed ID: 33050934
[TBL] [Abstract][Full Text] [Related]
18. Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma.
Sverrild A; Cerps S; Nieto-Fontarigo JJ; Ramu S; Hvidtfeldt M; Menzel M; Kearley J; Griffiths JM; Parnes JR; Porsbjerg C; Uller L
Allergy; 2024 Mar; 79(3):656-666. PubMed ID: 37846599
[TBL] [Abstract][Full Text] [Related]
19. Sounding the alarmins-The role of alarmin cytokines in asthma.
Gauvreau GM; Bergeron C; Boulet LP; Cockcroft DW; Côté A; Davis BE; Leigh R; Myers I; O'Byrne PM; Sehmi R
Allergy; 2023 Feb; 78(2):402-417. PubMed ID: 36463491
[TBL] [Abstract][Full Text] [Related]
20. Targeting TSLP in Asthma.
Parnes JR; Molfino NA; Colice G; Martin U; Corren J; Menzies-Gow A
J Asthma Allergy; 2022; 15():749-765. PubMed ID: 35685846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]